Pharmanutra Future Growth

Future criteria checks 5/6

Pharmanutra is forecast to grow earnings and revenue by 20.7% and 13.1% per annum respectively. EPS is expected to grow by 20.6% per annum. Return on equity is forecast to be 28.6% in 3 years.

Key information

20.7%

Earnings growth rate

20.6%

EPS growth rate

Personal Products earnings growth8.2%
Revenue growth rate13.1%
Future return on equity28.6%
Analyst coverage

Low

Last updated10 Sep 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:761 - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261482523272
12/31/20251312119222
12/31/20241141717202
6/30/2024108141520N/A
3/31/202410111212N/A
12/31/202310113-112N/A
9/30/20239512-512N/A
6/30/20239314-1912N/A
3/31/20238816-1514N/A
12/31/20228315-917N/A
9/30/20227916-519N/A
6/30/202276151019N/A
3/31/202273151420N/A
12/31/202168141520N/A
9/30/202165141316N/A
6/30/202160111215N/A
3/31/202157141315N/A
12/31/202057141012N/A
9/30/202058141111N/A
6/30/20205814711N/A
3/31/202055949N/A
12/31/2019548712N/A
9/30/201949838N/A
6/30/201950979N/A
3/31/201948968N/A
12/31/201847966N/A
9/30/201844856N/A
6/30/201841756N/A
3/31/2018406N/A6N/A
12/31/2017386N/A6N/A
9/30/2017375N/AN/AN/A
6/30/2017355N/AN/AN/A
3/31/2017344N/AN/AN/A
12/31/2016334N/A6N/A
12/31/2015263N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 761's forecast earnings growth (20.7% per year) is above the savings rate (0.8%).

Earnings vs Market: 761's earnings (20.7% per year) are forecast to grow faster than the German market (20.1% per year).

High Growth Earnings: 761's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 761's revenue (13.1% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: 761's revenue (13.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 761's Return on Equity is forecast to be high in 3 years time (28.6%)


Discover growth companies